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Abstract: Activity of acid sphingomyelinase has been im-
plicated in a number of diseases like acute lung injury,
sepsis or metastasis of melanoma cells. Here, we present a
sphingomyelinase FRET probe based on FAM/BODIPY dyes
for real-time monitoring of acid sphingomyelinase. The
probe gives rise to a tremendous increase in fluorescence
of the fluorescein FRET donor upon cleavage and we
show that this is, to a significant part, due to cleavage-as-
sociated phase transition, suggesting a more systematic
consideration of such effects for future probe develop-
ment. The probe allows for the first time to monitor rela-
tive sphingomyelinase activities of intact living cells by
flow cytometry.
Sphingolipids form a class of membrane lipids that are ubiqui-
tous in the plasma membranes of eukaryotes.[1] Less complex
intermediates of membrane sphingolipid biosynthesis and
degradation such as ceramide, sphingosine and sphingosine-1-
phosphate are important regulators of cell fate and are there-
fore the focus of various pharmaceutical strategies.[2–4] Sphin-
gomyelin, one of the most abundant lipids in eukaryotic
plasma membranes, is cleaved by sphingomyelinases in a
single step to yield ceramide and phosphoryl choline, thus
serving as a reservoir for the above lipid mediators. Among dif-
ferent isoenzymes, the acid sphingomyelinase (ASM) has
drawn most attention with regard to human disease.[5] ASM is
a soluble lipid hydrolase and ubiquitous in the acidic compart-
ments of eukaryotic cells. Different conditions can also trigger
localization of ASM into lipid rafts of the outer leaflet of the
plasma membrane.[6] Numerous reports suggest that inhibition
of ASM could be a promising strategy for treating a variety of
diseases like acute lung injury, major depression or metastasis
of melanoma.[5, 7] However, despite its potential as a drug
target, no potent drug-like inhibitors are known so far.[8]
Given the importance of ASM as a potential drug target and
the need for tools for convenient and effective testing of ASM
activities, we decided to develop sphingomyelin FRET sub-
strates. FRET probes, in contrast to quenched probes, turn-on
or turn-off probes, offer the possibility of ratio measurements.
The quotient of both, FRET donor and FRET acceptor fluores-
cence intensities reflects the degree of cleavage of the probe,
independent of its concentration.[8, 9] In a previous work we
have already synthesized a FRET substrate for the downstream
enzyme acid ceramidase. Although a nearly 100 % FRET effi-
ciency could be determined for the substrate, the ratio change
was moderate with about 3.5-fold.[10] Likewise, we recently syn-
thesized a FRET substrate for ASM with NBD as a FRET donor
and Nile red as a FRET acceptor, where the ratio change was
even lower, with a factor of about 3-fold. Closer investigation
showed that the cause for the small signal change was
quenching of the NBD dye upon cleavage and concomitant
lipid-water phase transition.[11] This caused us to utilize the
phase transition-triggered NBD quenching to develop a
second ASM probe with coumarine as FRET donor and NBD as
FRET acceptor. This simple trick yielded an about 80-fold ratio
change upon cleavage.[11] The latter probe was highly suitable
for monitoring enzymatic activity in vitro and due to its selec-
tive cleavage by ASM also suited for life cell imaging of
enzyme activity. However, the coumarine FRET donor with an
excitation optimum around 350 nm made use of a two-photon
excitation microscope necessary.[11] To address this shortcom-
ing, we now decided to make a new attempt towards a FRET
substrate excitable in the visible range. In order to keep the
polarity and membrane anchoring as close as possible to
nature and to fall back on already known sphingomyelin deriv-
atives, we decided to introduce a BODIPY dye into the fatty
acid part, and a relatively polar fluorescein (FAM) residue (Exc.
485 nm/ Em. 518 nm) into the choline analog head group
(Scheme 1). We were well aware of the pH dependence of fluo-
rescence of FAM, but due to the low costs and the manifold
possibilities of chemical modification, we decided for this dye
combination. For the synthesis of the envisioned probe, we
used the orthogonally protected sphingosyl-phosphoryletha-
nolamine intermediate 1, which was developed and described
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by us previously.[11] After removal of the phthalimide protection
group the resulting amine 2 was coupled to 5/6 carboxyfluor-
escein in the presence of N-hydroxysuccinimide (Scheme 1).
The resulting intermediate 3 was treated with hydrochloric
acid in dioxane to remove the remaining protecting groups. Fi-
nally, the crude deprotected intermediate was reacted with an
active ester of BODIPY hexanoic acid to afford the desired
FRET substrate 4.
Upon incubation of a micellar solution of the novel substrate
4 with acid sphingomyelinase, the BODIPY acceptor fluores-
cence appeared to be almost unchanged, similar to results
with the Nile red containing probes.[10–11] Surprisingly, the fluo-
rescence of FAM increased significantly by more than 100-fold
(Figure 1 A). Expectedly, the new substrate 4, enabled us to dif-
ferentiate between different concentrations/activities of ASM
(Figure 1 B). The reaching of a plateau value for the fluores-
cence (Figure 1 B–D) indicated complete conversion of the
probe, as shown by TLC separation after the experiments (Fig-
ure S2).
Surprised by the enormous sensitivity of the probe, we con-
sidered whether the unexpectedly high increase in FAM fluo-
rescence may not have been fueled by the destruction of the
FRET system alone, but also by the phase transition of the dye
from the micelle environment into the aqueous solution. This
would be the exact opposite of our very first ASM FRET probe,
where the released dye was quenched by transition from the
lipid micellar phase to the aqueous phase.
To investigate this further, we decided to synthesize a corre-
sponding substrate having only a FAM but not a BODIPY resi-
due. Towards this end, intermediate 3 was coupled with an un-
labeled fatty acid. Since palmitoylation resulted in a completely
insoluble and therefore hardly fluorescent product 5 b, a lauric
acid residue was introduced using the corresponding succini-
mide active ester (Scheme 1). As suspected beforehand, even
the mono-labeled probe 5 a without a FRET acceptor showed a
significant increase in fluorescence upon cleavage by ASM (Fig-
ure 1 C). Indeed, this increase was still about 20-fold. We there-
fore concluded that the FAM dye alone was subject to some
mode of quenching, while being bound to lipid micelles. Inter-
estingly, both probes yielded virtually the same end-point fluo-
rescence at 518 nm after cleavage, but the initial fluorescence
of the doubly labeled probe 4 was significantly lower (&7.5-
fold), suggesting that this part of FAM quenching was due to
FRET. The direct comparison also showed that the mono-la-
beled probe was cleaved much faster than the double-labeled
FRET probe (Figure 1 C). A detailed kinetic characterization con-
firmed this observation (4, KM = 8.9 mm ; Vmax = 3.1 mmol/(mg h);
5 a, KM = 4.2 mm, Vmax = 7.1 mmol/(mg h); see Figures S3–S10).
As in the case of our previously published probe, no cleavage
of the two probes by cell lysates of cells overexpressing neu-
tral sphingomyelinase 2 at neutral pH could be detected (data
not shown).
Since we knew about the pH dependence of FAM fluores-
cence, we wanted to investigate this effect for our probe in
more detail. Therefore, we set up the same enzymatic reaction
at four different pH values, 4.5, 5.0, 5.5 and 7.0 using sodium
acetate buffer or TRIS/HCl buffer, respectively (Figure 1 D). In
the literature, the pH optimum of acid sphingomyelinase is
usually given as “about 5”. An early study reports a value of
4.4, which was determined with radioactively labelled sub-
strate.[12] Another study gives a pH optimum of 5.0 to 5.5, but
the values were obtained with hexadecanoyl-p-nitrophenyl
phosphorylcholine as substrate.[13] From the recorded graphs
using the probe 5 a it was clearly visible, that the absolute
fluorescence increase was the largest at pH 5.5. This behavior
is easily explained by the fact that the fluorescence of fluores-
cein is increasing with higher pH.[14] However, direct compari-
son showed that initial slopes decreased with higher pH and
that the curve at pH 4.5 entered a plateau phase, while the
curves at higher pH values were still increasing, clearly demon-
strating a pH optimum below 5.0 under these conditions (Fig-
ure 1 D). At pH 7, the curve showed a significantly elevated ini-
tial fluorescence and only a marginal increase in fluorescence,
which seems to match with reports that acid sphingomyeli-
Scheme 1. Synthesis of probes 4 and 5. Reagents and conditions: a) H4N2·H2O, MeOH, 5.5 h, r.t. , 84 %; b) 5(6)-carboxyfluorescein, N-hydroxysuccinimide, DCC,
CH2Cl2, 4 h, r.t. , then NEt3, DMF, 20 h, r.t. , 66 %; c) 4 m HCl dioxane/iso-PrOH, 4 h, 70 8C, then 1.3 equiv. BODIPY TR-X SE, NEt3, pyridine/DMF, 10 h, r.t. , 59 % over
2 steps. d) 4 m HCl dioxane/iso-PrOH, 3.5 h, 70 8C, then 1.4 equiv. C11H23COOSu, NEt3, iso-PrOH/THF, 30 h, r.t. , 78 % over 2 steps or 1.2 equiv. C15H32COCl, DIPEA,
pyridine/CH2Cl2, 5.5 h, 0 8C, 12 % over 2 steps.




nase shows only about 5 % of its maximum activity at neutral
pH.[15] We were uncertain whether the pH dependence of the
FAM dye and the localization of ASM in the acidic compart-
ments of the cell would be compatible with a quantification of
ASM activities in living cells. However, an even bigger problem
with the use of confocal microscopy could be that, upon cleav-
age of the probe, FAM would transfer from a concentrated,
membrane-bound state into the aqueous phase and would
therefore be subject to a dilution effect that could counteract
the strong increase in fluorescence. Therefore, we decided to
use an application of the probe for flow cytometry (FC), be-
cause this method, in contrast to confocal methods, considers
the total fluorescence of the cell. In fact, FC-based analysis of
cellular ASM activity would provide a very fast and convenient
way to examine clinical samples or the in-cellulo activity of po-
tential ASM inhibitors. Until now, an in-cellulo characterization
of ASM inhibitors can only be performed by a tedious proce-
dure in which the cells are incubated with a radioactive or flu-
orescent probe together with the inhibitor. Finally, after pulse/
chase, lysis of the cell and extraction of the lipids and subse-
quent concentration and separation by TLC or HPLC analysis,
the in cellulo activity can be calculated, as reported very re-
cently.[16] To test, whether this procedure could be overcome
by using FC, we incubated L929 murine fibroblasts with the
FRET probe 4 (1 mm) and the fluorescence after different incu-
bation times was analyzed in the green (FAM) and red
(BODIPY) channel, respectively (not shown). The peak fluores-
cence in the FAM channel (about 5-fold compared to back-
ground) was measured after 30 minutes, whereupon this incu-
bation time was used as standard for all further measurements.
This increase in fluorescence is small compared to the increase
in vitro, which is likely attributed to the relatively high back-
ground fluorescence of the cells together with probably un-
complete cleavage of the probe. Further optimization in the
future may better exploit the inherent features of the probe.
To prove that this increase in fluorescence was really due to
the activity of the acid sphingomyelinase, cells were pre-treat-
ed with 10 mm amitriptyline for 24 h. This compound accumu-
lates in the endolysosomal compartment of the cell and leads
to a proteolytic degradation of ASM and some other lysosomal
lipid hydrolases.[6] Incubation with this drug led to significant
decrease of the mean fluorescence intensity (MFI) of the cells
in the FAM channel compared to vehicle-treated cells (Fig-
ure 2 A). The MFI of the BODIPY channel, however, was indistin-
guishable from the one for those cells that were not treated
with the inhibitor (Figure S1). A more detailed dose-dependent
study showed a very high agreement of the remaining ASM
activities for both the conventional and the FC-based method
(Figure 2 B). Therefore, we concluded that we have successfully
established a FC-based assay for acid sphingomyelinase in
living cells.
FRET probes are superior tools for monitoring enzyme activi-
ties in real time at high sensitivity and with high spatial resolu-
tion.[8] Above all, the possibility of ratiometric measurements
recommends FRET probes compared to other concepts such
as quenched probes. Here, we present a new FRET substrate
for the acid sphingomyelinase. Probe 4 shows a 100-fold ratio
change and we are not aware of a higher value from the litera-
ture. As in an earlier example in which a FRET acceptor led to a
dramatic amplification of the probe by a lipid-water phase
Figure 1. A) Probe 4 (1 mm, exc. 485 nm) before (black) and after (red) incubation with ASM. B) Probe 4 (1 mm, exc. 485 nm, em. 518 nm) in presence of 0
(black)/0.02 (green)/0.2 (blue)/2.0 (red) mg mL@1 ASM, over time. C) Comparison of probe 4 (black) with probe 5 a (red), each 1 mm, with 2.0 mg mL@1 ASM.
D) Probe 4 (1 mm) with 2.0 mg mL@1 ASM at pH 7 (green), pH 4.5 (black), pH 5.0 (red) and pH 5.5 (blue). Normalization was performed to the maximum ob-
served fluorescence, respectively.




transition, this principle was now shown in reverse for a FRET
donor. Indeed, also the mono-labeled probe 5 a can be used
for indicating ASM activities in vitro, but without the possibility
of ratio measurement. Phase transitions upon FRET probe
cleavage can be “friend or foe” and there is much to be sug-
gested that such effects should be investigated more thor-
oughly and included in the planning of new FRET probes in
the future. Moreover, we show that our new probe is suitable
for a fast, easy and reproducible assessment of cellular ASM ac-
tivities. The FC-based method could be superior for testing po-
tential ASM inhibitors because the conventional assay introdu-
ces lots of artifacts with the real inhibition being often under-
estimated or lost. Finally the FC-method could also be used in
clinical environments, for example, for an easy diagnosis of
Niemann-Pick disease type A and B, an inborn ASM deficien-
cy.[17]
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Figure 2. A) Flow cytometry (FC) analysis of L929 cells: Mean fluorescence
intensities (MFI) in the green channel. Black curve = cell w/o probe; blue
curve = cell with probe 4, but w/o inhibitor; red curve = cells with probe
4 plus 10 mm amitriptyline (24 h pre-treatment). B) ASM activity assay after
treatment with Amitriptyline for 24 h at the indicated concentrations. Black
curve: conventional ASM assay. Magenta curve: FC-based assay using
probe 4.
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